Surgical Neurology
Volume 67, Issue 2 , Pages 113-116 , February 2007

Nanotechnology approaches for drug and small molecule delivery across the blood brain barrier

  • Gabriel A. Silva, MSc, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author. Jacobs Retina Center, University of California, San Diego, La Jolla, CA 92037-0946, USA. Tel.: +1 858 822 4591; fax: +1 858 534 7985.

Received 15 August 2006 ,Accepted 21 August 2006.

References 

  1. Alyaudtin RN, Reichel A, Lobenberg R, Ramge P, Kreuter J, Begley DJ. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target. 2001;9:209–221
  2. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80–coated polybutylcyanoacrylate nanoparticles. Pharm Res. 1997;14:325–328
  3. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80–coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul. 1998;15:67–74
  4. Badruddoja MA, Black KL. Improving the delivery of therapeutic agents to CNS neoplasms: a clinical review. Front Biosci. 2006;11:1466–1478
  5. Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology. 2005;103:860–876
  6. Borm PJ, Kreyling W. Toxicological hazards of inhaled nanoparticles—potential implications for drug delivery. J Nanosci Nanotechnol. 2004;4:521–531
  7. Brigger I, Morizet J, Aubert G, Chacun H, Terrier-Lacombe MJ, Couvreur P, et al. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther. 2002;303:928–936
  8. Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C, Klein C, et al. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci. 2002;15:1317–1326
  9. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114–123
  10. Dupas B, Berreur M, Rohanizadeh R, Bonnemain B, Meflah K, Pradal G. Electron microscopy study of intrahepatic ultrasmall superparamagnetic iron oxide kinetics in the rat. Relation with magnetic resonance imaging. Biol Cell. 1999;91:195–208
  11. Ercolini AM, Miller SD. Mechanisms of immunopathology in murine models of central nervous system demyelinating disease. J Immunol. 2006;176:3293–3298
  12. Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem. 2004;11:413–424
  13. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm. 2000;49:103–109
  14. Garcia-Garcia E, Gil S, Andrieux K, Desmaele D, Nicolas V, Taran F, et al. A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. Cell Mol Life Sci. 2005;62:1400–1408
  15. Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590–1598
  16. Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, et al. Toxicological studies of doxorubicin bound to polysorbate 80–coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett. 2002;126:131–141
  17. Goppert TM, Muller RH. Plasma protein adsorption of Tween 80– and poloxamer 188–stabilized solid lipid nanoparticles. J Drug Target. 2003;11:225–231
  18. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80–coated nanoparticles. Pharm Res. 1999;16:1564–1569
  19. Kanwar JR. Anti-inflammatory immunotherapy for multiple sclerosis/experimental autoimmune encephalomyelitis (EAE) disease. Curr Med Chem. 2005;12:2947–2962
  20. Kornblith PL, Walker M. Chemotherapy for malignant gliomas. J Neurosurg. 1988;68:1–17
  21. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47:65–81
  22. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995;674:171–174
  23. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, et al. Direct evidence that polysorbate-80–coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res. 2003;20:409–416
  24. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target. 2002;10:317–325
  25. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm. 2002;28:1–13
  26. Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD. Brain uptake of thiamine-coated nanoparticles. J Control Release. 2003;93:271–282
  27. Lovin JD, Wesbey GE, Engelstad BL, Sosnovsky G, Moseley M, Tuck DL, et al. Magnetic field dependence of spin-lattice relaxation enhancement using piperidinyl nitroxyl spin-labels. Magn Reson Imaging. 1985;3:73–81
  28. Ma SH, Lepak LA, Hussain RJ, Shain W, Shuler ML. An endothelial and astrocyte co-culture model of the blood-brain barrier utilizing an ultra-thin, nanofabricated silicon nitride membrane. Lab Chip. 2005;5:74–85
  29. Miller G. Drug targeting. Breaking down barriers. Science. 2002;297:1116–1118
  30. Muldoon LL, Tratnyek PG, Jacobs PM, Doolittle ND, Christoforidis GA, Frank JA, et al. Imaging and nanomedicine for diagnosis and therapy in the central nervous system: report of the eleventh annual Blood-Brain Barrier Disruption Consortium meeting. AJNR Am J Neuroradiol. 2006;27:715–721
  31. Muller RH, Keck CM. Drug delivery to the brain—realization by novel drug carriers. J Nanosci Nanotechnol. 2004;4:471–483
  32. Nelson DF, Nelson JS, Davis DR, Chang CH, Griffin TW, Pajak TF. Survival and prognosis of patients with astrocytoma with atypical or anaplastic features. J Neurooncol. 1985;3:99–103
  33. Olbrich C, Gessner A, Kayser O, Muller RH. Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target. 2002;10:387–396
  34. Peira E, Marzola P, Podio V, Aime S, Sbarbati A, Gasco MR. In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide. J Drug Target. 2003;11:19–24
  35. Rousselle C, Clair P, Smirnova M, Kolesnikov Y, Pasternak GW, Gac-Breton S, et al. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector–mediated strategy. J Pharmacol Exp Ther. 2003;306:371–376
  36. Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci. 1998;87:1305–1307
  37. Silva GA. Introduction to nanotechnology and its applications to medicine. Surg Neurol. 2004;61:216–220
  38. Silva GA. Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system. Surg Neurol. 2005;63:301–306
  39. Silva GA. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci. 2006;7:65–74
  40. Silva GA. Small neuroscience: the nanostructure of the central nervous system and emerging nanotechnology applications. Curr Nanosci. 2005;3:225–236
  41. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235:179–192
  42. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer. 2004;109:759–767
  43. Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv. 2006;3:219–232
  44. Unger EC, Porter T, Culp W, Labell R, Matsunaga T, Zutshi R. Therapeutic applications of lipid-coated microbubbles. Adv Drug Deliv Rev. 2004;56:1291–1314
  45. Vinogradov SV, Batrakova EV, Kabanov AV. Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem. 2004;15:50–60
  46. Wesbey GE, Brasch RC, Goldberg HI, Engelstad BL, Moss AA. Dilute oral iron solutions as gastrointestinal contrast agents for magnetic resonance imaging; initial clinical experience. Magn Reson Imaging. 1985;3:57–64
  47. Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther. 2003;14:1–12

PII: S0090-3019(06)00696-3

doi: 10.1016/j.surneu.2006.08.033

Surgical Neurology
Volume 67, Issue 2 , Pages 113-116 , February 2007

Article Tools